ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China.
ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China.
Oral Oncol. 2021 Mar;114:105183. doi: 10.1016/j.oraloncology.2021.105183. Epub 2021 Jan 22.
Hypopharyngeal squamous cell carcinoma (HSCC) is an aggressive disease with poor prognosis, yet studies have largely been more qualitatively focused. Our study aims to quantitatively predict the risk of occult contralateral lymph node metastasis (cLNM) for HSCC patients with ipsilateral lymph node metastasis (iLNM). This will be based on pre- and post-operative indexes to guide the selection of prophylactic contralateral lymph node dissection (cLND) and postoperative adjuvant treatments. Multivariate analyses of 462 primary HSCC patients with iLNM showed that the age of patients, subregions of tumor, pathological T (pT) stage, ipsiateral MLS and metastatic lymph node number (MLN), and lymph nodal necrosis were independent cLNM risk factors. These were used to construct two nomograms that can effectively predict the contralateral neck involvement in HSCC patients with ipsilateral positive lymph nodes. The first nomogram (pre-model) provides quantitative assessment on the necessity of cLND, while the second nomogram (post-model) informs regions of interest for therapeutic radiation. Overall, patients deemed high-risk of cLNM by pre-model should receive cLND. Post-operation, patients deemed high-risk of cLNM by post-model should receive therapeutic radiation targeting contralateral neck lymph nodes, moderate-risk group warrants comparatively lower dose contralaterally, while low-risk group requires only follow-up.
下咽鳞状细胞癌(HSCC)是一种预后不良的侵袭性疾病,但研究主要集中在定性方面。我们的研究旨在定量预测伴有同侧淋巴结转移(iLNM)的 HSCC 患者隐匿性对侧淋巴结转移(cLNM)的风险。这将基于术前和术后指标来指导预防性对侧淋巴结清扫(cLND)和术后辅助治疗的选择。对 462 例伴有 iLNM 的原发性 HSCC 患者的多因素分析显示,患者年龄、肿瘤亚区、病理 T(pT)分期、同侧 MLS 和转移淋巴结数(MLN)以及淋巴结坏死是 cLNM 的独立危险因素。这些因素被用于构建两个列线图,可以有效地预测伴有同侧阳性淋巴结的 HSCC 患者对侧颈部受累情况。第一个列线图(预模型)提供了 cLND 必要性的定量评估,而第二个列线图(后模型)则告知了治疗性放疗的感兴趣区域。总体而言,预模型中被认为 cLNM 风险较高的患者应接受 cLND。术后,后模型中被认为 cLNM 风险较高的患者应接受针对对侧颈部淋巴结的治疗性放疗,中危组对侧需要相对较低剂量,而低危组只需随访。